<SEC-DOCUMENT>0001453687-20-000093.txt : 20200806
<SEC-HEADER>0001453687-20-000093.hdr.sgml : 20200806
<ACCEPTANCE-DATETIME>20200806080025
ACCESSION NUMBER:		0001453687-20-000093
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20200806
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200806
DATE AS OF CHANGE:		20200806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SELECTA BIOSCIENCES INC
		CENTRAL INDEX KEY:			0001453687
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37798
		FILM NUMBER:		201079904

	BUSINESS ADDRESS:	
		STREET 1:		480 ARSENAL WAY
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		617-923-1400

	MAIL ADDRESS:	
		STREET 1:		480 ARSENAL WAY
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>selectabiosciences8-kq.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:313ACC13A34652F58B8CB6AC24429152,x:6eb10790349b471780449ebab12cd042-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2020 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2019-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2019-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2019-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2019-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2019-01-31" xmlns:lea="http://fasb.org/dis/lea/2019-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2019-01-31" xmlns:guar="http://fasb.org/dis/guar/2019-01-31" xmlns:ru="http://fasb.org/dis/ru/2019-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2019-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2019-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2019-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2019-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:fs-insa="http://fasb.org/dis/fs-insa/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:cce="http://fasb.org/dis/cce/2019-01-31" xmlns:inv="http://fasb.org/dis/inv/2019-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:srt-std="http://fasb.org/srt-std/2019-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2019-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2019-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2019-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2019-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2019-01-31" xmlns:ceclcalc3l="http://fasb.org/dis/ceclcalc3l/2019-01-31" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:re="http://fasb.org/dis/re/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2019-01-31" xmlns:invco="http://fasb.org/dis/invco/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2019-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2019-01-31" xmlns:currency-ent-dep="http://xbrl.sec.gov/currency-ent-dep/2019-01-31" xmlns:aro="http://fasb.org/dis/aro/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:srt-all="http://fasb.org/srt-all/2019-01-31" xmlns:codification-part="http://fasb.org/codification-part/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:sec-re="http://fasb.org/dis/sec-re/2019-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2019-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2019-01-31" xmlns:equity="http://fasb.org/dis/equity/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:se="http://fasb.org/dis/se/2019-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2019-01-31" xmlns:edco="http://fasb.org/dis/edco/2019-01-31" xmlns:te="http://fasb.org/dis/te/2019-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2019-01-31" xmlns:hco="http://fasb.org/dis/hco/2019-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2019-01-31" xmlns:selb="http://www.selectabio.com/20200806" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:dr="http://fasb.org/dis/dr/2019-01-31" xmlns:ero="http://fasb.org/dis/ero/2019-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2019-01-31" xmlns:cecl="http://fasb.org/dis/cecl/2019-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2019-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2019-01-31" xmlns:ceclcalc2="http://fasb.org/dis/ceclcalc2/2019-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2019-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2019-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2019-01-31" xmlns:soi="http://fasb.org/stm/soi/2019-01-31" xmlns:diha="http://fasb.org/dis/diha/2019-01-31" xmlns:debt="http://fasb.org/dis/debt/2019-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2019-01-31" xmlns:bc="http://fasb.org/dis/bc/2019-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2019-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2019-01-31" xmlns:rd="http://fasb.org/dis/rd/2019-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2019-01-31" xmlns:eui="http://fasb.org/dis/eui/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ap="http://fasb.org/dis/ap/2019-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2019-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2019-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2019-01-31" xmlns:sr="http://fasb.org/dis/sr/2019-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2019-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2019-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2019-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2019-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2019-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2019-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2019-01-31" xmlns:oi="http://fasb.org/dis/oi/2019-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2019-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2019-01-31" xmlns:cc="http://fasb.org/dis/cc/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2019-01-31" xmlns:disops="http://fasb.org/dis/disops/2019-01-31" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:cn-part="http://fasb.org/cn-part/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2019-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2019-01-31" xmlns:ts="http://fasb.org/dis/ts/2019-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2019-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2019-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:ni="http://fasb.org/dis/ni/2019-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2019-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2019-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2019-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2019-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2019-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2019-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2019-01-31" xmlns:ir="http://fasb.org/dis/ir/2019-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2019-01-31" xmlns:foct="http://fasb.org/dis/foct/2019-01-31" xmlns:soc="http://fasb.org/stm/soc/2019-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2019-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2019-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2019-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:con="http://fasb.org/dis/con/2019-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2019-01-31" xmlns:eps="http://fasb.org/dis/eps/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2019-01-31" xmlns:pay="http://fasb.org/dis/pay/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:tin-part="http://fasb.org/tin-part/2019-01-31" xmlns:acec="http://fasb.org/dis/acec/2019-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2019-01-31" xmlns:nt="http://fasb.org/dis/nt/2019-01-31" xmlns:spc="http://fasb.org/stm/spc/2019-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2019-01-31" xmlns:ides="http://fasb.org/dis/ides/2019-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2019-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:regop="http://fasb.org/dis/regop/2019-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2019-01-31" xmlns:com="http://fasb.org/stm/com/2019-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2019-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2019-01-31" xmlns:exch-ent-dep="http://xbrl.sec.gov/exch-ent-dep/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ei="http://fasb.org/dis/ei/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="D2020Q2Aug6" name="dei:AmendmentFlag" id="Fact-1FCF7FA80A095694ABCAC7A1F3BBB92F-wk-Fact-1FCF7FA80A095694ABCAC7A1F3BBB92F" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="D2020Q2Aug6" name="dei:EntityCentralIndexKey" id="Fact-676729EA6D9B53678E3A57602E6FF678-wk-Fact-676729EA6D9B53678E3A57602E6FF678">0001453687</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="selb-20200806.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="D2020Q2Aug6">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-08-06</xbrli:startDate>
			<xbrli:endDate>2020-08-06</xbrli:endDate>
		</xbrli:period>
	</xbrli:context></ix:resources></ix:header></div><div><a id="sF09207EF2D8857558B88310A77F5BB8D"></a></div><div style="line-height:120%;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Washington, D.C. 20549</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM&#160;</span><span><ix:nonNumeric id="d17232300e86-wk-Fact-F0928E649F1554EDBD9893735789D4E3" name="dei:DocumentType" contextRef="D2020Q2Aug6"><span style="font-size:18pt;font-weight:bold;">8-K</span></ix:nonNumeric></span></div><div style="line-height:120%;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">CURRENT REPORT</span></div><div style="line-height:120%;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">the Securities Exchange Act of 1934</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date of Report (Date of earliest event reported): </span><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d17232300e111-wk-Fact-6D813489E8D9570C8A96F41B2BD564EB" name="dei:DocumentPeriodEndDate" contextRef="D2020Q2Aug6" format="ixt:datemonthdayyearen">August 6, 2020</ix:nonNumeric></span></span></span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:18pt;"><span><ix:nonNumeric id="d17232300e119-wk-Fact-9997A27FB6DF5D6E98C144D4ADF08A8A" name="dei:EntityRegistrantName" contextRef="D2020Q2Aug6"><span style="font-size:18pt;font-weight:bold;">SELECTA BIOSCIENCES,&#160;INC.</span></ix:nonNumeric></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</span></div><div style="line-height:120%;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:30%;"></td><td style="width:4%;"></td><td style="width:31%;"></td><td style="width:4%;"></td><td style="width:31%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d17232300e144-wk-Fact-845F5FEA62135A85B7896E5B25F95FC1" name="dei:EntityIncorporationStateCountryCode" contextRef="D2020Q2Aug6" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d17232300e154-wk-Fact-D3ABD921926E562FA18B20D306590498" name="dei:EntityFileNumber" contextRef="D2020Q2Aug6">001-37798</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d17232300e164-wk-Fact-D579DD0A29365ACA9E2113D82B07D419" name="dei:EntityTaxIdentificationNumber" contextRef="D2020Q2Aug6">26-1622110</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(State or other jurisdiction </span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">of incorporation)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Commission</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">File Number)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(IRS Employer</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identification No.)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span><ix:nonNumeric id="d17232300e207-wk-Fact-22B7FAF673FC5E7DB0B2882F50C1A255" name="dei:EntityAddressAddressLine1" contextRef="D2020Q2Aug6"><span style="font-weight:bold;">65 Grove Street,</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span><ix:nonNumeric id="d17232300e212-wk-Fact-9B0724025A0A522881E7EE57A61D2E50" name="dei:EntityAddressCityOrTown" contextRef="D2020Q2Aug6"><span style="font-weight:bold;">Watertown,</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span><ix:nonNumeric id="d17232300e217-wk-Fact-70D7150657025B4DB028AF9439CF4E41" name="dei:EntityAddressStateOrProvince" contextRef="D2020Q2Aug6"><span style="font-weight:bold;">MA</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span><ix:nonNumeric id="d17232300e222-wk-Fact-41B923F674805BB9AB2D78D550952173" name="dei:EntityAddressPostalZipCode" contextRef="D2020Q2Aug6"><span style="font-weight:bold;">02472</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;text-indent:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Address of principal executive offices)(Zip Code)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(</span><span><ix:nonNumeric id="d17232300e237-wk-Fact-AB737C7A949D57689C7805BDFEB2B09B" name="dei:CityAreaCode" contextRef="D2020Q2Aug6"><span style="font-weight:bold;">617</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">) </span><span><ix:nonNumeric id="d17232300e242-wk-Fact-BD20A6F2511E5A2A837B6FA14E273832" name="dei:LocalPhoneNumber" contextRef="D2020Q2Aug6"><span style="font-weight:bold;">923-1400</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;text-indent:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Registrant&#8217;s telephone number, including area code</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">N/A</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Former name or former address, if changed since last report)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:12%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial Unicode MS;font-size:9pt;"><span><ix:nonNumeric id="d17232300e277-wk-Fact-D4E922C70EDD55C4AA680516D89848EB" name="dei:WrittenCommunications" contextRef="D2020Q2Aug6" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial Unicode MS;font-size:9pt;"><span><ix:nonNumeric id="d17232300e299-wk-Fact-C07EE687D51A54778E58260836F50DCD" name="dei:SolicitingMaterial" contextRef="D2020Q2Aug6" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial Unicode MS;font-size:9pt;"><span><ix:nonNumeric id="d17232300e321-wk-Fact-E383F3BEAC475DE4A9FF06455F992CD5" name="dei:PreCommencementTenderOffer" contextRef="D2020Q2Aug6" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial Unicode MS;font-size:9pt;"><span><ix:nonNumeric id="d17232300e343-wk-Fact-9FC97600B5EE560990D97A09563B0411" name="dei:PreCommencementIssuerTenderOffer" contextRef="D2020Q2Aug6" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;">&#160;&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:40%;"></td><td style="width:19%;"></td><td style="width:41%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities registered pursuant to Section 12(b) of the Act:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Title of each class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trading Symbol(s)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Name of each exchange on which registered</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d17232300e426-wk-Fact-2671E67A6A235AB4A1F18B4B1F38729D" name="dei:Security12bTitle" contextRef="D2020Q2Aug6">Common Stock (Par Value $0.0001)</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d17232300e431-wk-Fact-034485C3AD7E5236A87BEBCC34D2C0BB" name="dei:TradingSymbol" contextRef="D2020Q2Aug6">SELB</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d17232300e436-wk-Fact-1D9EBCDE2D51511BA5FF0D182159024D" name="dei:SecurityExchangeName" contextRef="D2020Q2Aug6" format="ixt-sec:exchnameen">The Nasdaq Global Market</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;">&#160;&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emerging growth company  </span><span><ix:nonNumeric id="d17232300e465-wk-Fact-B882F45392275F17B4968BC42EBAC7C7" name="dei:EntityEmergingGrowthCompany" contextRef="D2020Q2Aug6" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9746;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span><ix:nonNumeric id="d17232300e475-wk-Fact-4500EAC1FF29598CBA446D622865C08A" name="dei:EntityExTransitionPeriod" contextRef="D2020Q2Aug6" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9746;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:9px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:18%;"></td><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:22%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="s6DD67722F4EC546C925D783C792CD0A6"></a></div><div><br/></div><div style="line-height:174%;padding-bottom:16px;text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2.02. Results of Operations and Financial Condition.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 6, 2020, Selecta Biosciences, Inc. announced its financial results for the three and six months ended June 30, 2020. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report and on Form 8-K.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information contained in Item 2.02 of this Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:2px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01. Financial Statements and Exhibits.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:65px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(d)&#160;Exhibits</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:11%;"></td><td style="width:5%;"></td><td style="width:84%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit</span></div><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">No.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit991earningsrele.htm"><span style="font-family:inherit;font-size:10pt;">99.1</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit991earningsrele.htm"><span style="font-family:inherit;font-size:10pt;">Press Release issued on August 6, 2020</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">104</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></div></td></tr></table></div></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="s0AA0E0FCDB335E20A6BD438492DA5AD2"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:5%;"></td><td style="width:46%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">SELECTA BIOSCIENCES,&#160;INC.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date: August 6, 2020</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">By:</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ Carsten Brunn, Ph.D.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Carsten Brunn, Ph.D.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</span></div></td></tr></table></div></div><div><br/></div>	</div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit991earningsrele.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s659757B2E0F856D295942F78FC9E33F9"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 99.1</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><img src="selectalogoa06.jpg" alt="selectalogoa06.jpg" style="height:74px;width:204px;"></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Selecta Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Updates</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">Closed strategic licensing agreement with Sobi for SEL-212 for $100 million in initial payments and up to $630 million in potential milestones, and tiered double-digit royalties</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">Entered into research license and option agreement with Sarepta for the use of the ImmTOR&#8482; immune tolerance platform in Sarepta&#8217;s gene therapy programs in certain neuromuscular diseases</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">Gene therapy program in MMA in collaboration with AskBio on track to enter the clinic in the first half of 2021; preliminary data expected in the second half of 2021</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">Phase 3 clinical program of SEL-212 to commence with Sobi in Q3 2020; on track to report topline data from ongoing head-to-head COMPARE trial in Q3 2020</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">Cash runway into the first quarter of 2023</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">Company to host conference call today at 8:30 a.m. ET</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Watertown, Mass., August 6, 2020 </font><font style="font-family:inherit;font-size:11pt;">- </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Selecta Biosciences, Inc.</font><font style="font-family:inherit;font-size:11pt;">&#32;(NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR, today reported financial results for the second quarter ended June 30, 2020 and provided corporate updates.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;This is a transformational time for Selecta, as we reinforce our position as a leader in immune tolerance. The strategic licensing agreement with Sobi puts us in a financial position that allows us to maximize efforts to unlock the full potential of the ImmTOR immune tolerance platform, by optimizing the efficacy and safety of biologics, enabling re-dosing of life saving gene therapies, and creating novel immunotherapies for autoimmune diseases,&#8221; said Carsten Brunn, Ph.D., President and CEO of Selecta. &#8220;We remain committed to the development of SEL-212, and look forward to the initiation of the Phase 3 clinical program with Sobi in the third quarter of this year and the topline data readout from the Phase 2 COMPARE trial, also in the third quarter. We also look forward to advancing our gene therapy program in MMA to the clinic in the first half of 2021, and for the submission of an IND for our autoimmune diseases program, also in 2021.&#8221;</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Recent Highlights and Anticipated Upcoming Milestones:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Closed Strategic Licensing Agreement with Sobi for SEL-212, the Company&#8217;s Phase 3-ready Novel Treatment for Chronic Refractory Gout: </font><font style="font-family:inherit;font-size:11pt;">The Company announced the closing of a strategic licensing agreement with Sobi for SEL-212, the Company&#8217;s lead product candidate </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:48px;text-align:left;"><font style="font-family:inherit;font-size:11pt;">leveraging the ImmTOR immune tolerance platform. Sobi assumes responsibility for all development, regulatory, and commercial activities, and expenses in all markets outside China, while Selecta will run the Phase 3 study on behalf of Sobi, at Sobi&#8217;s expense. Selecta will also maintain manufacturing of ImmTOR, for which Sobi will reimburse Selecta for activities relating to SEL-212. The initial payments to Selecta total $100 million. Sobi must pay $75 million in cash as an upfront license fee within 45 days of the effective date and has paid $25 million in cash in a private placement of Selecta common stock at $4.62 per share. Selecta is also eligible to receive potential development, regulatory, and commercial milestone payments of up to $630 million, and tiered double-digit royalties on net sales.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Entered into Research License and Option Agreement with Sarepta for the Use of ImmTOR in Certain Neuromuscular Diseases: </font><font style="font-family:inherit;font-size:11pt;">Selecta and Sarepta reached an agreement which provides Sarepta with the option to license the rights to develop and commercialize the ImmTOR platform for use in select neuromuscular diseases; Duchenne muscular dystrophy (DMD) and certain limb-girdle muscular dystrophies (LGMDs). Sarepta will evaluate its investigational gene therapies in combination with ImmTOR to mitigate the formation of neutralizing antibodies. Sarepta has made an initial payment to Selecta, and Selecta is eligible to receive certain pre-clinical milestone fees.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Two Key Clinical Milestones for SEL-212: </font><font style="font-family:inherit;font-size:11pt;">Selecta and Sobi anticipate initiating the Phase 3 clinical program in the third quarter of 2020. Selecta will take the lead running the Phase 3 program, at Sobi&#8217;s expense. The Phase 3 clinical program will consist of two double blinded, placebo-controlled trials of SEL-212. Each trial is expected to enroll 105 patients and have 35 patients receiving 0.1 mg/kg of ImmTOR and 0.2 mg/kg of pegadricase, 35 patients receiving 0.15 mg/kg of ImmTOR and 0.2 mg/kg of pegadricase, and 35 patients receiving placebo. The primary endpoint of the Phase 3 clinical trials is the maintenance of serum uric acid (SUA) levels of &lt;6mg/dL at six months. One of the trials will have a six-month extension. In addition, the</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">Company expects topline results from the Phase 2 COMPARE clinical trial in Q3 2020. This head-to-head study of a once-monthly dose of SEL-212 (ImmTOR + pegadricase) compared to biweekly doses of pegloticase is expected to read out on schedule. The primary endpoint of the COMPARE trial is the maintenance of serum uric acid (SUA) levels of &lt;6mg/dL at three and six months.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Timeline for Gene Therapy and Autoimmune Diseases Programs Confirmed: </font><font style="font-family:inherit;font-size:11pt;">The Company&#8217;s gene therapy program in methylmalonic acidemia, or MMA, in collaboration with AskBio, is expected to enter the clinic in the first half of 2021, with preliminary data expected in 2H 2021. In addition, Selecta intends to submit its Investigational New Drug Application (IND) for its autoimmune disease program in 2021. The first indication will be IgA nephropathy, a kidney disease that occurs when an antibody called immunoglobulin A (IgA) accumulates in the kidneys. The second indication is expected to be primary biliary cholangitis, or PBC, an autoimmune disease that causes progressive destruction of the bile ducts. Both diseases have well-defined target antigens, significant unmet medical need, and are well suited to the application of Selecta&#8217;s ImmTOR immune tolerance platform.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Appointed Peter G. Traber, MD, to the Position of Chief Medical Officer: </font><font style="font-family:inherit;font-size:11pt;">Dr. Traber,</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">who has been serving in the same position in an interim capacity, joined the Company full-time as of August 1, 2020. Dr. Traber has a broad range of experience in large pharma, biotech, and academia, and will oversee medical affairs, program management, and all aspects of clinical </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:48px;text-align:left;"><font style="font-family:inherit;font-size:11pt;">development and strategy, as well as provide scientific and clinical guidance for potential business development initiatives.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Second Quarter 2020 Financial Results:</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Cash Position:</font><font style="font-family:inherit;font-size:11pt;">&#32;Selecta had $</font><font style="font-family:inherit;font-size:11pt;">61.4 million</font><font style="font-family:inherit;font-size:11pt;">&#32;in cash, cash equivalents, and restricted cash as of June 30, 2020, which compares to cash, cash equivalents, and restricted cash of $91.6 million as of December 31, 2019. Selecta believes its available cash, cash equivalents, and restricted cash as of June 30, 2020, together with the $25 million payment received from Sobi under the Sobi Private Placement in July and the expected payment from Sobi of $75 million under the Sobi License, which is due 45 days after the effective date, will enable Selecta to fund operating expenses and capital expenditure requirements into the first quarter of 2023.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Net cash used in operating activities was </font><font style="font-family:inherit;font-size:11pt;">$23.5 million</font><font style="font-family:inherit;font-size:11pt;">&#32;for the six months ended June 30, 2020, as compared to $27.4 million for the same period in 2019.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Research and Development Expenses:</font><font style="font-family:inherit;font-size:11pt;">&#32;Research and development expenses for the </font><font style="font-family:inherit;font-size:11pt;">second</font><font style="font-family:inherit;font-size:11pt;">&#32;quarter 2020 were </font><font style="font-family:inherit;font-size:11pt;">$10.7 million</font><font style="font-family:inherit;font-size:11pt;">, which compares with $12.1 million for the same period in 2019. The decrease in costs was primarily the result of reduced expense for the Phase 2 COMPARE trial for SEL-212 offset by increases for the gene therapy program in collaboration with AskBio, and salaries and benefits.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">General and Administrative Expenses: </font><font style="font-family:inherit;font-size:11pt;">General and administrative expenses for the </font><font style="font-family:inherit;font-size:11pt;">second</font><font style="font-family:inherit;font-size:11pt;">&#32;quarter 2020 were </font><font style="font-family:inherit;font-size:11pt;">$5.6 million</font><font style="font-family:inherit;font-size:11pt;">, which compares with $4.1 million for the same period in 2019. The increase in costs was the result of expenses incurred for salaries, legal and professional fees offset by decreased travel expense.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Net Loss: </font><font style="font-family:inherit;font-size:11pt;">For the </font><font style="font-family:inherit;font-size:11pt;">second</font><font style="font-family:inherit;font-size:11pt;">&#32;quarter 2020, Selecta reported a net loss of </font><font style="font-family:inherit;font-size:11pt;">$24.1 million</font><font style="font-family:inherit;font-size:11pt;">, or </font><font style="font-family:inherit;font-size:11pt;">$0.25</font><font style="font-family:inherit;font-size:11pt;">&#32;per share, compared to a net loss of $16.4 million, or $0.37 per share, for the same period in 2019.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Conference Call and Webcast Reminder:</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Selecta management will host a conference call at 8:30 a.m. ET today to provide a corporate update and review the company&#8217;s </font><font style="font-family:inherit;font-size:11pt;">second</font><font style="font-family:inherit;font-size:11pt;">&#32;quarter 2020 financial results. Individuals may participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and using confirmation code 10138605. Investors and the public can access the live and archived webcast of this call via the Investors &amp; Media section of the company&#8217;s website, </font><font style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;">www.selectabio.com.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">About Selecta Biosciences, Inc.</font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Selecta Biosciences, Inc.&#160;is a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance technology (ImmTOR) platform.&#160;Selecta&#160;plans to combine ImmTOR with a range of biologic therapies for rare and serious diseases that require new treatment options due to high immunogenicity. The company&#8217;s current proprietary pipeline includes ImmTOR-powered therapeutic enzyme and gene therapy product candidates. SEL-212, the company&#8217;s lead product candidate, is being developed to treat chronic refractory gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. Selecta&#8217;s proprietary gene therapy product candidates are in preclinical development for certain rare inborn errors of metabolism and incorporate ImmTOR with the goal of addressing barriers to repeat </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">administration.&#160;Selecta&#160;is based in&#160;Watertown, Massachusetts. For more information, please visit </font><font style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;">www.selectabio.com</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Forward-Looking Statements</font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">Any statements in this press release about the future expectations, plans and prospects of&#160;Selecta Biosciences, Inc.&#160;(&#8220;the company&#8221;), including without limitation, the company&#8217;s actions regarding the monitoring and assessment of COVID-19 on the company&#8217;s operations, clinical trials and manufacturing, Sarepta&#8217;s plans to evaluate its gene therapies in combination with the company&#8217;s ImmTOR technology, the possibility of Sarepta exercising an option to enter into a commercial license agreement, Sarepta&#8217;s achievement of any milestones that would trigger payment(s) to Selecta, the unique proprietary technology platform of the company and the unique proprietary platform of its partners, the potential of ImmTOR to enable re-dosing of AAV gene therapy, the ability of the company&#8217;s ImmTOR platform to unlock the full potential of biologic therapies, the potential treatment applications for product candidates utilizing the ImmTOR platform in areas such as enzyme therapy and gene therapy, the novelty of treatment paradigms that Sarepta is able to develop in combination with the company&#8217;s ImmTOR technology, the potential of any therapies developed by Sarepta in combination with the company&#8217;s ImmTOR technology to fulfill unmet medical needs, the company&#8217;s plan to apply its ImmTOR technology platform to a range of biologics for rare and serious diseases, the clinical development, commercialization, and regulatory activities related to SEL-212 by either the company or Sobi, including with respect to anticipated geographic markets, the anticipated timing of the planned Phase 3 clinical trial, the potential market opportunity for SEL-212, the potential of SEL-212 to fulfill unmet needs in chronic refractory gout patients including sustained SUA reduction, reduced flares, and repeated once monthly dosing, as well as the ability to dose longer than the current standard of care, the company&#8217;s and Sobi&#8217;s commercial plans, the expected upfront, milestone, and royalty-based payments to the company under the strategic licensing agreement with Sobi, the company&#8217;s development of a product candidate to treat an autoimmune indication, including for IgA nephropathy, the timing and execution of company&#8217;s plans to file an IND for such product candidate,, the potential of the ImmTOR technology platform generally and the company&#8217;s ability to grow its strategic partnerships, the sufficiency of the company&#8217;s cash, cash equivalents and short-term investments, and other statements containing the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;hypothesize,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;would,&#8221; and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, the following: the uncertainties inherent in the initiation, completion and cost of clinical trials including their uncertain outcomes, the effect of the COVID-19 outbreak on any of the company&#8217;s planned or ongoing clinical trials, manufacturing activities, supply chain and operations, the availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a particular clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, the unproven approach of the company&#8217;s ImmTOR technology, Sarepta&#8217;s ability to research and develop therapeutic candidates using the company&#8217;s ImmTOR technology, undesirable side effects of the company&#8217;s product candidates, its reliance on third parties to manufacture its product candidates and to conduct its clinical trials as well as the impact of the COVID-19 outbreak on those third parties and their ability to continue their operations, the company&#8217;s inability to maintain its existing or future collaborations, licenses or contractual relationships, its inability to protect its proprietary technology and intellectual property, management&#8217;s ability to perform as expected, potential delays in regulatory approvals, Sobi and/or Sarepta&#8217;s ability to make up-front and milestone payments, the company&#8217;s business development strategy,&#160; the availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements, the company&#8217;s recurring losses </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">from operations and negative cash flows from operations raise substantial doubt regarding its ability to continue as a going concern, substantial fluctuation in the price of its common stock including stock market fluctuations that occur as a result of the COVID-19 outbreak, and other important factors discussed in the &#8220;Risk Factors&#8221; section of the company&#8217;s most recent Quarterly Report on Form 10-Q, and in other filings that the company makes with the&#160;Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent the company&#8217;s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The company specifically disclaims any intention to update any forward-looking statements included in this press release.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Selecta Biosciences, Inc. and Subsidiaries</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Balance Sheets</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Amounts in thousands, except share data and par value)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:64%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Current assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">59,730</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">89,893</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Restricted cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">278</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">279</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Prepaid expenses and other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,044</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,495</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Total current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">61,052</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">96,667</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,301</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,222</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Right-of-use asset, net </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">11,474</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">301</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Long-term restricted cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,379</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,379</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">75,206</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">99,569</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Liabilities and stockholders&#8217; equity (deficit)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Current liabilities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,242</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accrued expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">9,308</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">13,492</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Loan payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">8,384</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">18,905</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Lease liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,648</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">372</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Deferred revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,928</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,674</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Total current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">22,510</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">34,943</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Non&#8209;current liabilities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Loan payable, net of current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,449</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Lease liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">10,120</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Deferred revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">16,412</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">14,680</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Warrant liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">32,767</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">41,549</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">88,258</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">91,172</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Stockholders&#8217; equity (deficit):</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Common stock, $0.0001 par value; 200,000,000 shares authorized; 100,847,810 and 86,325,547 shares issued and outstanding as of June 30, 2020 and December 31,&#160;2019, respectively</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Additional paid-in capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">370,944</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">348,664</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(379,454</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(335,753</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accumulated other comprehensive loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(4,552</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(4,523</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Total stockholders&#8217; equity (deficit)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(13,052</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">8,397</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Total liabilities and stockholders&#8217; equity (deficit)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">75,206</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">99,569</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Selecta Biosciences, Inc. and Subsidiaries</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Operations and Comprehensive Loss</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Amounts in thousands, except share data and per share data)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:37%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Unaudited)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Grant and collaboration revenue</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">23</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">10,730</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">12,134</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">25,454</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">19,487</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,637</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4,114</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">9,735</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">8,627</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">16,367</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">16,248</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">35,189</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">28,114</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(16,367</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(16,235</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(35,189</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(28,091</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Investment income</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">246</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">253</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">523</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Foreign currency transaction (loss), net</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(42</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(10</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">40</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(40</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(205</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(400</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(478</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(796</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Change in fair value of warrant liabilities</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(7,539</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(8,385</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Other (expense), net</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">59</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">58</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(64</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(24,081</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(16,394</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(43,701</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(28,468</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Other comprehensive loss:</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Foreign currency translation adjustment</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(29</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">29</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Unrealized gain on securities</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Total comprehensive loss</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(24,050</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(16,386</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(43,730</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(28,436</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net loss per share:</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Basic and diluted</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(0.25</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(0.37</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(0.46</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(0.68</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Weighted average common shares outstanding:</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Basic and diluted</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">96,785,915</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">44,855,083</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">95,754,714</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">41,668,902</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"># # #</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">For Media:</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Joshua R. Mansbach</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Solebury Trout</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">+1-646-378-2964</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;">jmansbach@soleburytrout.com</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">For Investors:</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Lee M. Stern</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Solebury Trout</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">+1-646-378-2922</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;">lstern@soleburytrout.com</font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>selb-20200806.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.selectabio.com/20200806" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:selb="http://www.selectabio.com/20200806" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="selb-20200806_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="selb-20200806_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="selb-20200806_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="selb-20200806_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="CoverPageDocument" roleURI="http://www.selectabio.com/role/CoverPageDocument">
        <link:definition>0001000 - Document - Cover Page Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>selb-20200806_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.selectabio.com/role/CoverPageDocument" xlink:href="selb-20200806.xsd#CoverPageDocument" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.selectabio.com/role/CoverPageDocument" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>selb-20200806_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.selectabio.com/role/CoverPageDocument" xlink:href="selb-20200806.xsd#CoverPageDocument" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.selectabio.com/role/CoverPageDocument" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>selb-20200806_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_CoverAbstract_339801340D5F83054D00814790BEF5D7_label_en-US" xlink:label="lab_dei_CoverAbstract_77580F476D605B0C872B165E3A43CB55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_77580F476D605B0C872B165E3A43CB55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_77580F476D605B0C872B165E3A43CB55" xlink:to="lab_dei_CoverAbstract_77580F476D605B0C872B165E3A43CB55" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_10C0DCBDD9667ABAEBEF814790C1F3D9_terseLabel_en-US" xlink:label="lab_dei_DocumentType_53966A8A9E2F5E2DB177E17B36288EC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_10C0DCBDD9667ABAEBEF814790C1F3D9_label_en-US" xlink:label="lab_dei_DocumentType_53966A8A9E2F5E2DB177E17B36288EC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_53966A8A9E2F5E2DB177E17B36288EC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_53966A8A9E2F5E2DB177E17B36288EC7" xlink:to="lab_dei_DocumentType_53966A8A9E2F5E2DB177E17B36288EC7" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_FD1AB04137BF6E73E6E1814790C215EB_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_406B135A108557C1A703CEEC4EE022FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_FD1AB04137BF6E73E6E1814790C215EB_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_406B135A108557C1A703CEEC4EE022FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_406B135A108557C1A703CEEC4EE022FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_406B135A108557C1A703CEEC4EE022FA" xlink:to="lab_dei_DocumentPeriodEndDate_406B135A108557C1A703CEEC4EE022FA" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_2164EF11E0A887AA572A814790C29777_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_27131264444C578AB90B57A701FF103C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_2164EF11E0A887AA572A814790C29777_label_en-US" xlink:label="lab_dei_EntityRegistrantName_27131264444C578AB90B57A701FF103C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_27131264444C578AB90B57A701FF103C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_27131264444C578AB90B57A701FF103C" xlink:to="lab_dei_EntityRegistrantName_27131264444C578AB90B57A701FF103C" xlink:type="arc" />
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_73328B4C9387BD7E5643814790C3B6DC_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_DFF2EE06520458EA9D2A08BA10F6BF7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_73328B4C9387BD7E5643814790C3B6DC_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_DFF2EE06520458EA9D2A08BA10F6BF7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_DFF2EE06520458EA9D2A08BA10F6BF7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_DFF2EE06520458EA9D2A08BA10F6BF7C" xlink:to="lab_dei_EntityIncorporationStateCountryCode_DFF2EE06520458EA9D2A08BA10F6BF7C" xlink:type="arc" />
    <link:label id="lab_dei_EntityFileNumber_445C3D6FCD7F5075C9B3814790C32109_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber_3B9B8C0B6B325DC9A0C7EBB759A1983F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_445C3D6FCD7F5075C9B3814790C32109_label_en-US" xlink:label="lab_dei_EntityFileNumber_3B9B8C0B6B325DC9A0C7EBB759A1983F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_3B9B8C0B6B325DC9A0C7EBB759A1983F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_3B9B8C0B6B325DC9A0C7EBB759A1983F" xlink:to="lab_dei_EntityFileNumber_3B9B8C0B6B325DC9A0C7EBB759A1983F" xlink:type="arc" />
    <link:label id="lab_dei_EntityTaxIdentificationNumber_66BFF89780B415984B94814790C3EAD1_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_56F2F9A3A26350B3A4BCE990A1EB6685" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_66BFF89780B415984B94814790C3EAD1_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_56F2F9A3A26350B3A4BCE990A1EB6685" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_56F2F9A3A26350B3A4BCE990A1EB6685" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_56F2F9A3A26350B3A4BCE990A1EB6685" xlink:to="lab_dei_EntityTaxIdentificationNumber_56F2F9A3A26350B3A4BCE990A1EB6685" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine1_6DC1DAB364A5CC5283DD814790C39955_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_15DBE23DD8625C6DA40453CC31AEA93D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_6DC1DAB364A5CC5283DD814790C39955_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_15DBE23DD8625C6DA40453CC31AEA93D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_15DBE23DD8625C6DA40453CC31AEA93D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_15DBE23DD8625C6DA40453CC31AEA93D" xlink:to="lab_dei_EntityAddressAddressLine1_15DBE23DD8625C6DA40453CC31AEA93D" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressCityOrTown_F6D9FE81FB0385EF7F9B814790C36E82_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_8571B02AE992500C8F0DD675FA386B6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_F6D9FE81FB0385EF7F9B814790C36E82_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_8571B02AE992500C8F0DD675FA386B6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_8571B02AE992500C8F0DD675FA386B6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_8571B02AE992500C8F0DD675FA386B6C" xlink:to="lab_dei_EntityAddressCityOrTown_8571B02AE992500C8F0DD675FA386B6C" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressStateOrProvince_590D219CCE87072B3688814790C3AD05_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_F2DAB37FC5435ABCA0488E80A4520FB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_590D219CCE87072B3688814790C3AD05_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_F2DAB37FC5435ABCA0488E80A4520FB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_F2DAB37FC5435ABCA0488E80A4520FB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_F2DAB37FC5435ABCA0488E80A4520FB8" xlink:to="lab_dei_EntityAddressStateOrProvince_F2DAB37FC5435ABCA0488E80A4520FB8" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressPostalZipCode_1D08A8DBFE1D2D439581814790C3EAC1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_6865B3FEB3F3520B9C33B740E971FC01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_1D08A8DBFE1D2D439581814790C3EAC1_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_6865B3FEB3F3520B9C33B740E971FC01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_6865B3FEB3F3520B9C33B740E971FC01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_6865B3FEB3F3520B9C33B740E971FC01" xlink:to="lab_dei_EntityAddressPostalZipCode_6865B3FEB3F3520B9C33B740E971FC01" xlink:type="arc" />
    <link:label id="lab_dei_CityAreaCode_6910563BC29F74DEBE94814790C4DB0F_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode_8B84326E34065410A7DC9B56C321781A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_6910563BC29F74DEBE94814790C4DB0F_label_en-US" xlink:label="lab_dei_CityAreaCode_8B84326E34065410A7DC9B56C321781A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_8B84326E34065410A7DC9B56C321781A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_8B84326E34065410A7DC9B56C321781A" xlink:to="lab_dei_CityAreaCode_8B84326E34065410A7DC9B56C321781A" xlink:type="arc" />
    <link:label id="lab_dei_LocalPhoneNumber_6C566844ABAA1E9D2737814790C466FA_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber_0BB8E6878A3856DE9FA0727B46258551" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_6C566844ABAA1E9D2737814790C466FA_label_en-US" xlink:label="lab_dei_LocalPhoneNumber_0BB8E6878A3856DE9FA0727B46258551" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_0BB8E6878A3856DE9FA0727B46258551" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_0BB8E6878A3856DE9FA0727B46258551" xlink:to="lab_dei_LocalPhoneNumber_0BB8E6878A3856DE9FA0727B46258551" xlink:type="arc" />
    <link:label id="lab_dei_WrittenCommunications_152B6B41C39693C94F26814790C4D13C_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications_8FBFB6EDE5AC543A80FF036BF73C7D08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_152B6B41C39693C94F26814790C4D13C_label_en-US" xlink:label="lab_dei_WrittenCommunications_8FBFB6EDE5AC543A80FF036BF73C7D08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_dei_WrittenCommunications_8FBFB6EDE5AC543A80FF036BF73C7D08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications_8FBFB6EDE5AC543A80FF036BF73C7D08" xlink:to="lab_dei_WrittenCommunications_8FBFB6EDE5AC543A80FF036BF73C7D08" xlink:type="arc" />
    <link:label id="lab_dei_SolicitingMaterial_249104ADB93387385B01814790C43EA4_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial_D2F6EE8682A05EFD9C96615B6024FECA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_249104ADB93387385B01814790C43EA4_label_en-US" xlink:label="lab_dei_SolicitingMaterial_D2F6EE8682A05EFD9C96615B6024FECA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_dei_SolicitingMaterial_D2F6EE8682A05EFD9C96615B6024FECA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial_D2F6EE8682A05EFD9C96615B6024FECA" xlink:to="lab_dei_SolicitingMaterial_D2F6EE8682A05EFD9C96615B6024FECA" xlink:type="arc" />
    <link:label id="lab_dei_PreCommencementTenderOffer_A4E82E3458ECBE36FE7E814790C4F8FB_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer_C8DAF3EF9B035DBE8F011F2EF0A07575" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_A4E82E3458ECBE36FE7E814790C4F8FB_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer_C8DAF3EF9B035DBE8F011F2EF0A07575" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_dei_PreCommencementTenderOffer_C8DAF3EF9B035DBE8F011F2EF0A07575" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer_C8DAF3EF9B035DBE8F011F2EF0A07575" xlink:to="lab_dei_PreCommencementTenderOffer_C8DAF3EF9B035DBE8F011F2EF0A07575" xlink:type="arc" />
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_36ACEEE025D6F63F48EB814790C426FC_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer_43D07BF3AA93577CAA422E3533CF6776" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_36ACEEE025D6F63F48EB814790C426FC_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer_43D07BF3AA93577CAA422E3533CF6776" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_43D07BF3AA93577CAA422E3533CF6776" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer_43D07BF3AA93577CAA422E3533CF6776" xlink:to="lab_dei_PreCommencementIssuerTenderOffer_43D07BF3AA93577CAA422E3533CF6776" xlink:type="arc" />
    <link:label id="lab_dei_Security12bTitle_3FCCCA82170B4ABDCD7E814790C549D0_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle_57EA5C2406EA534BBB1B7BC972C7881A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_3FCCCA82170B4ABDCD7E814790C549D0_label_en-US" xlink:label="lab_dei_Security12bTitle_57EA5C2406EA534BBB1B7BC972C7881A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_57EA5C2406EA534BBB1B7BC972C7881A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_57EA5C2406EA534BBB1B7BC972C7881A" xlink:to="lab_dei_Security12bTitle_57EA5C2406EA534BBB1B7BC972C7881A" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_60C62E54C8A6B2323734814790C5CBFF_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_95DB409D23765EFFAEAF7877B295421F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_60C62E54C8A6B2323734814790C5CBFF_label_en-US" xlink:label="lab_dei_TradingSymbol_95DB409D23765EFFAEAF7877B295421F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_95DB409D23765EFFAEAF7877B295421F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_95DB409D23765EFFAEAF7877B295421F" xlink:to="lab_dei_TradingSymbol_95DB409D23765EFFAEAF7877B295421F" xlink:type="arc" />
    <link:label id="lab_dei_SecurityExchangeName_E66BE3793044951CDA15814790C54ECA_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName_A0BA846457AB5AA8924659525E2A0DF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_E66BE3793044951CDA15814790C54ECA_label_en-US" xlink:label="lab_dei_SecurityExchangeName_A0BA846457AB5AA8924659525E2A0DF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_A0BA846457AB5AA8924659525E2A0DF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_A0BA846457AB5AA8924659525E2A0DF0" xlink:to="lab_dei_SecurityExchangeName_A0BA846457AB5AA8924659525E2A0DF0" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9B8AF219853D4E25C78D814790C5A54F_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_27C7CF2901825A71BDB081ACE6817DB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9B8AF219853D4E25C78D814790C5A54F_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_27C7CF2901825A71BDB081ACE6817DB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_27C7CF2901825A71BDB081ACE6817DB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_27C7CF2901825A71BDB081ACE6817DB8" xlink:to="lab_dei_EntityEmergingGrowthCompany_27C7CF2901825A71BDB081ACE6817DB8" xlink:type="arc" />
    <link:label id="lab_dei_EntityExTransitionPeriod_6B56C617EC8E2067A9F4814790C5942D_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod_119A42199FE350E6B97C6B172A47C1D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_6B56C617EC8E2067A9F4814790C5942D_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod_119A42199FE350E6B97C6B172A47C1D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_119A42199FE350E6B97C6B172A47C1D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod_119A42199FE350E6B97C6B172A47C1D6" xlink:to="lab_dei_EntityExTransitionPeriod_119A42199FE350E6B97C6B172A47C1D6" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_D1F5D25EFCE2B24F9663814790C56FEF_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_20C15BA105B050D6AE839E3667E8378A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_D1F5D25EFCE2B24F9663814790C56FEF_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_20C15BA105B050D6AE839E3667E8378A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_20C15BA105B050D6AE839E3667E8378A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_20C15BA105B050D6AE839E3667E8378A" xlink:to="lab_dei_EntityCentralIndexKey_20C15BA105B050D6AE839E3667E8378A" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_F7D0CDB96C1827A52587814790C61E2C_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_46CCD01C152A5096A04867AFA47D0A63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_F7D0CDB96C1827A52587814790C61E2C_label_en-US" xlink:label="lab_dei_AmendmentFlag_46CCD01C152A5096A04867AFA47D0A63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_46CCD01C152A5096A04867AFA47D0A63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_46CCD01C152A5096A04867AFA47D0A63" xlink:to="lab_dei_AmendmentFlag_46CCD01C152A5096A04867AFA47D0A63" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>selb-20200806_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.selectabio.com/role/CoverPageDocument" xlink:href="selb-20200806.xsd#CoverPageDocument" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.selectabio.com/role/CoverPageDocument" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_77580F476D605B0C872B165E3A43CB55" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_53966A8A9E2F5E2DB177E17B36288EC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77580F476D605B0C872B165E3A43CB55" xlink:to="loc_dei_DocumentType_53966A8A9E2F5E2DB177E17B36288EC7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_406B135A108557C1A703CEEC4EE022FA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77580F476D605B0C872B165E3A43CB55" xlink:to="loc_dei_DocumentPeriodEndDate_406B135A108557C1A703CEEC4EE022FA" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_27131264444C578AB90B57A701FF103C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77580F476D605B0C872B165E3A43CB55" xlink:to="loc_dei_EntityRegistrantName_27131264444C578AB90B57A701FF103C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_DFF2EE06520458EA9D2A08BA10F6BF7C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77580F476D605B0C872B165E3A43CB55" xlink:to="loc_dei_EntityIncorporationStateCountryCode_DFF2EE06520458EA9D2A08BA10F6BF7C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_3B9B8C0B6B325DC9A0C7EBB759A1983F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77580F476D605B0C872B165E3A43CB55" xlink:to="loc_dei_EntityFileNumber_3B9B8C0B6B325DC9A0C7EBB759A1983F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_56F2F9A3A26350B3A4BCE990A1EB6685" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77580F476D605B0C872B165E3A43CB55" xlink:to="loc_dei_EntityTaxIdentificationNumber_56F2F9A3A26350B3A4BCE990A1EB6685" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_15DBE23DD8625C6DA40453CC31AEA93D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77580F476D605B0C872B165E3A43CB55" xlink:to="loc_dei_EntityAddressAddressLine1_15DBE23DD8625C6DA40453CC31AEA93D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_8571B02AE992500C8F0DD675FA386B6C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77580F476D605B0C872B165E3A43CB55" xlink:to="loc_dei_EntityAddressCityOrTown_8571B02AE992500C8F0DD675FA386B6C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_F2DAB37FC5435ABCA0488E80A4520FB8" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77580F476D605B0C872B165E3A43CB55" xlink:to="loc_dei_EntityAddressStateOrProvince_F2DAB37FC5435ABCA0488E80A4520FB8" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_6865B3FEB3F3520B9C33B740E971FC01" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77580F476D605B0C872B165E3A43CB55" xlink:to="loc_dei_EntityAddressPostalZipCode_6865B3FEB3F3520B9C33B740E971FC01" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_8B84326E34065410A7DC9B56C321781A" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77580F476D605B0C872B165E3A43CB55" xlink:to="loc_dei_CityAreaCode_8B84326E34065410A7DC9B56C321781A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_0BB8E6878A3856DE9FA0727B46258551" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77580F476D605B0C872B165E3A43CB55" xlink:to="loc_dei_LocalPhoneNumber_0BB8E6878A3856DE9FA0727B46258551" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_dei_WrittenCommunications_8FBFB6EDE5AC543A80FF036BF73C7D08" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77580F476D605B0C872B165E3A43CB55" xlink:to="loc_dei_WrittenCommunications_8FBFB6EDE5AC543A80FF036BF73C7D08" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_dei_SolicitingMaterial_D2F6EE8682A05EFD9C96615B6024FECA" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77580F476D605B0C872B165E3A43CB55" xlink:to="loc_dei_SolicitingMaterial_D2F6EE8682A05EFD9C96615B6024FECA" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_dei_PreCommencementTenderOffer_C8DAF3EF9B035DBE8F011F2EF0A07575" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77580F476D605B0C872B165E3A43CB55" xlink:to="loc_dei_PreCommencementTenderOffer_C8DAF3EF9B035DBE8F011F2EF0A07575" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_43D07BF3AA93577CAA422E3533CF6776" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77580F476D605B0C872B165E3A43CB55" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_43D07BF3AA93577CAA422E3533CF6776" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_57EA5C2406EA534BBB1B7BC972C7881A" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77580F476D605B0C872B165E3A43CB55" xlink:to="loc_dei_Security12bTitle_57EA5C2406EA534BBB1B7BC972C7881A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_95DB409D23765EFFAEAF7877B295421F" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77580F476D605B0C872B165E3A43CB55" xlink:to="loc_dei_TradingSymbol_95DB409D23765EFFAEAF7877B295421F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_A0BA846457AB5AA8924659525E2A0DF0" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77580F476D605B0C872B165E3A43CB55" xlink:to="loc_dei_SecurityExchangeName_A0BA846457AB5AA8924659525E2A0DF0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_27C7CF2901825A71BDB081ACE6817DB8" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77580F476D605B0C872B165E3A43CB55" xlink:to="loc_dei_EntityEmergingGrowthCompany_27C7CF2901825A71BDB081ACE6817DB8" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_119A42199FE350E6B97C6B172A47C1D6" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77580F476D605B0C872B165E3A43CB55" xlink:to="loc_dei_EntityExTransitionPeriod_119A42199FE350E6B97C6B172A47C1D6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_20C15BA105B050D6AE839E3667E8378A" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77580F476D605B0C872B165E3A43CB55" xlink:to="loc_dei_EntityCentralIndexKey_20C15BA105B050D6AE839E3667E8378A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_46CCD01C152A5096A04867AFA47D0A63" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77580F476D605B0C872B165E3A43CB55" xlink:to="loc_dei_AmendmentFlag_46CCD01C152A5096A04867AFA47D0A63" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>selectalogoa06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 selectalogoa06.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#T17AI9@  34T *@    @ ! $[  (
M   .   (2H=I  0    !   (6)R=  $    <   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $QA=7)I92!'
M;&%V:6X   60 P "    %   $*:0!  "    %   $+J2D0 "     S4S  "2
MD@ "     S4S  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK"\776I66A_:=)8H\<@,K
M!0Q"8.>"/7%.\*Z\-=TH-(?]*APDPQC)[,/8_P \UE[6/M/9O<Z?JT_8>W6U
M[>GJ>5-J1\#_ !:N9M3C8V[3R,2!N)BDR58>XR,_0BNN\7?$OP\WAB[M],NQ
M>W-Y"T*(B,NT,""S$@8P#TZYQ]1U/B/PGI/BJS$&K6^YD_U<T9VR1_0^GL<C
MVKFK+X-^&+.\2>1KZ[5#GR9YEV-]=J@_K7H^TI3M*=[H^;6%Q5%2I4;<LN_2
MY!\'M.N(-#O-1G&V*]D40@]2$W M],DC\*]%IL44<,*10HL<:*%1$& H'  '
M84ZN:I/GDY'IX:BJ%*--= HHHJ#H"BBB@ HHHH ***XOQCXK\@/I6EOF=OEF
ME3^#_9'^UZ^GUZ95:L:4>:1T8;#SQ-10A_PQTEKKNFWNH26-K=I)<1@ED /;
MK@XP?PK0KF/"'A<:/#]LO5S>R+C&>(E]/KZG\/7/3T493E"\U9CQ,*4*CC1=
MTNOG_D%%%%:G,%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH \Q^,=TZ+I, 8B-C*Y&>"1M _+)_.N^T+3;?2-$M;.T50B1C+
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M)EA*P4E5XYY(QCK42IR@[-&U+%4JT6X.]OO.:^+_ /R3>]_ZZQ?^ABIOA/\
M\DQTK_MM_P"CGKS'QCXQ\::OX=>S\0:#_9]E)(I:7[%+'D@Y W.2.H_2G^$/
M&?C;2_#<%CH.@_;[&)G$<WV*:3DL6(W(0.I-=7LI>RY?,\I8RG]<]I9VY;;>
M9[Y1572[BXN]'L[B^@^SW,L"/-#C'EN5!9>?0Y%8OBSQUH_@^)!J#M+=2*6C
MM80"Y'J>RC/<^^,X-<:BV[(]J56$(<\G9'245XRGQ;\7:O<2/X=\-1S6ZX&T
M02W#+]60@?I4UA\:=2L+\VWB[0O).1G[.C1/&/=')S^8K;ZO4.)9EAV]W;O8
M]@HKC]?\>6\'P^F\2>''AO,.B()0<*Q8 AER"" >GT/2M7P;KTOB;PC8ZM<0
MI#+<*V]$)*Y5RI(SV.W..V>IZUDX24>9G5'$4YU/9Q=W:_R-NBBBH-PHHHH
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MTH1VMI]Z.PHHHKC/;"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY(&164*,Y/561U5L=1IQO%\SZ):GLFEZM8:U9"[TJZCNH-Q7?&<X(Z@^A_\
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M/_(GZA_US'_H0K6C_$CZHY,;_NM3_"_R.+\'^#]/\0:/+=WLURCK.8P(F4#
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M.,))QV:N:97B*E>E)57=Q;5^]@HHHKF/5"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH \D^%]G<P>/M6\Z"1/)@DCDW+]UC(N ?<[3^5>MT45C1I
M>RARWN=^/QCQM;VK5M$ON"BBBMC@"BBB@ HHHH *Q_%D,D_A/4(X4+N8LA5'
M)P03^@K8HJH2Y9*78RK4_:TI4WU37WGD/A_Q;?\ A[3WM+>SCE1Y3)F0-D$@
M#M]*U/\ A96J_P#0-@_)O\:]*HKLEB:4G=T_Q/$IY7BZ4%"&):2_N_\ !/,V
M\3^+?$"^1IEH8%8X+V\9'7L78X7Z\5O^$?!@T5A?:@5EOB/E Y6('KSW/O\
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/ 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>selectabiosciences8-kq_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="selb-20200806.xsd" xlink:type="simple"/>
    <context id="D2020Q2Aug6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
        </entity>
        <period>
            <startDate>2020-08-06</startDate>
            <endDate>2020-08-06</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="D2020Q2Aug6"
      id="Fact-1FCF7FA80A095694ABCAC7A1F3BBB92F-wk-Fact-1FCF7FA80A095694ABCAC7A1F3BBB92F">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="D2020Q2Aug6"
      id="Fact-676729EA6D9B53678E3A57602E6FF678-wk-Fact-676729EA6D9B53678E3A57602E6FF678">0001453687</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="D2020Q2Aug6"
      id="d17232300e86-wk-Fact-F0928E649F1554EDBD9893735789D4E3">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="D2020Q2Aug6"
      id="d17232300e111-wk-Fact-6D813489E8D9570C8A96F41B2BD564EB">2020-08-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="D2020Q2Aug6"
      id="d17232300e119-wk-Fact-9997A27FB6DF5D6E98C144D4ADF08A8A">SELECTA BIOSCIENCES,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="D2020Q2Aug6"
      id="d17232300e144-wk-Fact-845F5FEA62135A85B7896E5B25F95FC1">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="D2020Q2Aug6"
      id="d17232300e154-wk-Fact-D3ABD921926E562FA18B20D306590498">001-37798</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="D2020Q2Aug6"
      id="d17232300e164-wk-Fact-D579DD0A29365ACA9E2113D82B07D419">26-1622110</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="D2020Q2Aug6"
      id="d17232300e207-wk-Fact-22B7FAF673FC5E7DB0B2882F50C1A255">65 Grove Street,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="D2020Q2Aug6"
      id="d17232300e212-wk-Fact-9B0724025A0A522881E7EE57A61D2E50">Watertown,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="D2020Q2Aug6"
      id="d17232300e217-wk-Fact-70D7150657025B4DB028AF9439CF4E41">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="D2020Q2Aug6"
      id="d17232300e222-wk-Fact-41B923F674805BB9AB2D78D550952173">02472</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="D2020Q2Aug6"
      id="d17232300e237-wk-Fact-AB737C7A949D57689C7805BDFEB2B09B">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="D2020Q2Aug6"
      id="d17232300e242-wk-Fact-BD20A6F2511E5A2A837B6FA14E273832">923-1400</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="D2020Q2Aug6"
      id="d17232300e277-wk-Fact-D4E922C70EDD55C4AA680516D89848EB">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="D2020Q2Aug6"
      id="d17232300e299-wk-Fact-C07EE687D51A54778E58260836F50DCD">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="D2020Q2Aug6"
      id="d17232300e321-wk-Fact-E383F3BEAC475DE4A9FF06455F992CD5">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="D2020Q2Aug6"
      id="d17232300e343-wk-Fact-9FC97600B5EE560990D97A09563B0411">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="D2020Q2Aug6"
      id="d17232300e426-wk-Fact-2671E67A6A235AB4A1F18B4B1F38729D">Common Stock (Par Value $0.0001)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="D2020Q2Aug6"
      id="d17232300e431-wk-Fact-034485C3AD7E5236A87BEBCC34D2C0BB">SELB</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="D2020Q2Aug6"
      id="d17232300e436-wk-Fact-1D9EBCDE2D51511BA5FF0D182159024D">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="D2020Q2Aug6"
      id="d17232300e465-wk-Fact-B882F45392275F17B4968BC42EBAC7C7">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="D2020Q2Aug6"
      id="d17232300e475-wk-Fact-4500EAC1FF29598CBA446D622865C08A">true</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140654350572584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page Document<br></strong></div></th>
<th class="th"><div>Aug. 06, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  06,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SELECTA BIOSCIENCES,&#160;INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-1622110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">65 Grove Street,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Watertown,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">923-1400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock (Par Value $0.0001)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SELB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001453687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MG9A=<^(V%(:OM[]"0SN=W1D2VX(8LB7,$$):9O-!8[J9::<7PA:@B2VQLKS
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MN:5/NN_"'-H6%-Q4K66E8^)RKU"OVD L2G?DXMZ[Z(KY,(%$"!E69K%&\W&
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M BHL""H+.P^^=I)*TM W.Y4QV:^W.YW;N RH#Z(ODSJGJD^=OD[6XR3AJ0-
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M              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (  Q !E$D'INBK0   /@!   :
M          "  ><0  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    (  Q !E%ED'F2&0$  ,\#   3              "  <P1  !;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  !83      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="selectabiosciences8-kq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Cover Page Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/CoverPageDocument</Role>
      <ShortName>Cover Page Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="selectabiosciences8-kq.htm">selectabiosciences8-kq.htm</File>
    <File>exhibit991earningsrele.htm</File>
    <File>selb-20200806.xsd</File>
    <File>selb-20200806_cal.xml</File>
    <File>selb-20200806_def.xml</File>
    <File>selb-20200806_lab.xml</File>
    <File>selb-20200806_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "selectabiosciences8-kq.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "calculationLink": {
     "local": [
      "selb-20200806_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "selb-20200806_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "selectabiosciences8-kq.htm"
     ]
    },
    "labelLink": {
     "local": [
      "selb-20200806_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "selb-20200806_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "selb-20200806.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "selb",
   "nsuri": "http://www.selectabio.com/20200806",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selectabiosciences8-kq.htm",
      "contextRef": "D2020Q2Aug6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Cover Page Document",
     "role": "http://www.selectabio.com/role/CoverPageDocument",
     "shortName": "Cover Page Document",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selectabiosciences8-kq.htm",
      "contextRef": "D2020Q2Aug6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001453687-20-000093-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001453687-20-000093-xbrl.zip
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MW.^_\>#^_^Y.9M Z4"64T6Y(;_Z'<><+4$L#!!0    (  Q !E$YKZTCI0$
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M60PH)K'__0YU<2Q+LCA#TG:!UHI+#Y\YGO?,#$DI/_]R?37+ON;E8EK,7YW
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MU.&)3")"1(N B!%F8<762B,MXXPI)$B$8)MG5'!P;<8VT/5\LYOU_#(MEN[
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M@B^:0V_G@^HS-#VHVSX?9M'BXCR*[U%1+A)8HA$TUAL%DSA9G-[&$UR@*_R
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MXJ?SP;B<)!?_#U!+ 0(4 Q0    (  Q !E%TTNA.KB@  )%/ @ :
M      "  0    !E>&AI8FET.3DQ96%R;FEN9W-R96QE+FAT;5!+ 0(4 Q0
M   (  Q !E'HH*FV10,  'L1   1              "  >8H  !S96QB+3(P
M,C P.# V+GAS9%!+ 0(4 Q0    (  Q !E'P,C9L/P$  (@"   5
M      "  5HL  !S96QB+3(P,C P.# V7V-A;"YX;6Q02P$"% ,4    "  ,
M0 91.:^M(Z4!  #:!0  %0              @ ',+0  <V5L8BTR,#(P,#@P
M-E]D968N>&UL4$L! A0#%     @ #$ &4>^O1EOL"P  <FH  !4
M     ( !I"\  '-E;&(M,C R,# X,#9?;&%B+GAM;%!+ 0(4 Q0    (  Q
M!E'C68U Q@8  #<W   5              "  <,[  !S96QB+3(P,C P.# V
M7W!R92YX;6Q02P$"% ,4    "  ,0 91_$+5P'X8  #4M@  &@
M    @ &\0@  <V5L96-T86)I;W-C:65N8V5S."UK<2YH=&U02P4&      <
,!P#; 0  <EL

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
